{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=53", "query": { "condition": "Head and Neck Squamous Cell Carcinomas", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1530, "total_pages": 153, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T10:21:13.649Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Carcinoma", "Head and Neck Cancer Stage III", "Head and Neck Cancer Stage IV", "Head and Neck Cancer Metastatic", "Cancer", "Cancer of Esophagus", "Cancer, Metastatic", "Cancer of Head and Neck", "Cancer of Mouth", "Cancer of Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tadalafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-04-07", "completion_date": "2024-01-09", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03993353" }, { "nct_id": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Mutant", "Glioblastoma, IDH-wildtype", "Brain Metastases, Adult", "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Microsatellite Instability-High Solid Malignant Tumor", "Mismatch Repair Deficient Solid Malignant Tumor", "Microsatellite Instability-High Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma", "Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "NEO212 Oral Capsule", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2023-11-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 8, "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047379" }, { "nct_id": "NCT05337631", "title": "Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HNSCC", "Oral Cavity Cancer", "Oropharynx Cancer", "Hypopharynx Cancer", "Larynx Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University Hospital Freiburg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1500, "start_date": "2021-06-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05337631" }, { "nct_id": "NCT02764593", "title": "Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "RTOG Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2016-06", "completion_date": "2022-02-21", "has_results": false, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 11, "location_summary": "Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02764593" }, { "nct_id": "NCT03498378", "title": "Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kathryn Gold", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-06-06", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03498378" }, { "nct_id": "NCT00002515", "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Head and Neck Cancer", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "1992-10", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002515" }, { "nct_id": "NCT00004226", "title": "Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Loma Linda, California • Tampa, Florida", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004226" }, { "nct_id": "NCT00005638", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005638" }, { "nct_id": "NCT00003443", "title": "Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-07", "completion_date": "2001-05", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003443" }, { "nct_id": "NCT00485485", "title": "Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Cancer" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2007-01", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-10-24T10:21:13.649Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485485" } ] }